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Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with potential effects
on offspring both genetically and through altered intrauterine environment. Metformin, which
ameliorate hormonal disturbances in non-pregnant women with PCOS is increasingly used
in pregnancy. It passes the placenta, and the evidence on potential consequences for off-
spring endocrine development is scarce. We explore the potential effects of maternal PCOS
status and intrauterine metformin exposure on offspring steroid hormone levels.
Design
This is a follow-up study of 5–10 years old children from the PregMet-study–a randomized
controlled trial comparing metformin (2000 mg/day) to placebo during PCOS pregnancies.
Of the 255 children invited, 117 (46%) were included.
Methods
There was no intervention in this follow-up study. Outcomes were serum levels of andro-
stenedione, testosterone, SHBG, cortisol, 17-hydroxyprogesterone, 11-deoxycortisol and
calculated free testosterone converted to gender-and age adjusted z-scores from a Norwe-
gian reference population. These were compared in i) placebo-exposed children versus
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children from the reference population (z-score zero) by the deviation in z-score by one-
sample t-tests and ii) metformin versus placebo-exposed children by two-sample t-tests.
Holm-Bonferroni adjustments were performed to account for multiple endpoints.
Results
Girls of mothers with PCOS (n = 30) had higher mean z-scores of androstenedione (0.73
(95% confidence interval (CI) 0.41 to 1.06), p<0.0001), testosterone (0.76 (0.51 to 1.00),
p<0.0001), and free testosterone (0.99 (0.67 to 1.32), p<0.0001) than the reference popula-
tion. Metformin-exposed boys (n = 31) tended to have higher 11-deoxycortisol z-score than
placebo-exposed boys (n = 24) (mean difference 0.65 (95% CI 0.14–1.17), p = 0.014).
Conclusion
Maternal PCOS status was associated with elevated androgens in 5- to 10-year-old daugh-
ters, which might indicate earlier maturation and increased risk of developing PCOS. An
impact of metformin in pregnancy on steroidogenesis in children born to mothers with
PCOS cannot be excluded. Our findings need confirmation in studies that include partici-
pants that have entered puberty.
Introduction
Polycystic ovary syndrome (PCOS) is a common endocrine disorder among women in fertile
age [1]. Central in the etiology are insulin resistance and insulin-induced hyperandrogenism.
PCOS implies increased risk of pregnancy complications, and probably an altered intrauterine
environment, with potential long-term consequences for the offspring [2, 3]. There is growing
evidence of increased cardiometabolic risk factors in children of women with PCOS [4–7].
Also, studies have suggested earlier pubertal maturation, higher androgen levels and risk of
later PCOS among their daughters, while others found no endocrine alterations in these chil-
dren [8–13]. In our previous follow-up study of the PregMet-studies, where pregnant women
with PCOS were randomized to metformin or placebo, the placebo exposed offspring had
higher waist circumference compared to a national reference population, whereas those
exposed to metformin in addition had higher body mass index (BMI) and increased preva-
lence of obesity [14, 15]. More knowledge about the effects of maternal PCOS is needed to pre-
vent the long-term health challenges in the offspring.
Metformin tends to ameliorate hormonal disturbances in non-pregnant women with
PCOS [16, 17]. It has therefore been used to improve pregnancy outcomes in PCOS [18], and
was recently found to decrease the prevalence of late miscarriage and pre-term births in a large
individual patient data meta-analysis [19]. Two systematic reviews and meta-analyses on met-
formin vs placebo or insulin in pregnancy found a higher weight among metformin exposed
children [20, 21]. High BMI is in general associated with earlier pubertal maturation [22–24].
There is limited knowledge about how metformin in utero might impact hormonal levels and
pubertal maturation; except for higher free testosterone among metformin-exposed boys, met-
formin did not associate with any endocrine alterations in newborns from the PregMet-study
[25]. In a study by Tertti et al., metformin treatment of gestational diabetes did not affect tes-
ticular size in a follow-up of 5-year-old boys [26].
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In this 5–10 year follow-up of the PregMet-study, we assessed adrenal, gonadal and adi-
pose tissue steroid hormones related to PCOS, in addition to hepatic sex-hormone-binding
globulin (SHBG), which is inversely associated with obesity and insulin resistance; and cal-
culated free testosterone [27–29]. We explore the potential effects of maternal PCOS status
and intrauterine metformin exposure on offspring steroid hormone levels by comparing
steroid hormones of i) children born to PCOS mothers and children from a Norwegian ref-
erence population, and ii) metformin-exposed and placebo-exposed children born to
women with PCOS.
Materials and method
The present paper represents secondary analyses of the PedMet-study: a follow-up of children
born in “the Metformin in Pregnant PCOS women study” (the PregMet-study) which was a
double blind, randomized, placebo-controlled study. The PedMet Clinical Trial Registration:
ClinicalTrials.gov number NCT03259919. The PregMet Clinical Trial Registration: Clinical-
Trials.gov number NCT00159536.
The Committee for Medical Research Ethics of Health Region IV, Norway, approved both
the PregMet-study (project number 145.04) and the follow-up study (project number 2014/
96). The declaration of Helsinki and the Good Clinical Practice guidelines were followed
throughout the studies. The Consort 2010 statement and checklist has been followed when
reporting, as appropriate. Written, informed consent was obtained from each child’s parent or
guardian before inclusion.
The PregMet-study: Between 2005 and 2009, 257 pregnant women aged 18–45 years, with
PCOS according to the Rotterdam criteria were included with 274 singleton pregnancies at
5–12 weeks of gestation, at 11 study centers in Norway. Seventeen women participated twice
[30]. Participants were randomized to metformin (2000 mg daily) or placebo throughout preg-
nancy. An intake of>85% of the tablets was self-reported in 80% of the participants. Details of
design, objectives, and results are described elsewhere [18].
The follow-up study–The PedMet-study: Of the 274 pregnancies in the PregMet-study, 255
children were eligible, and their parent or guardian were asked to their permission to
participate.
Participating children were included at St. Olavs University Hospital in Trondheim and
nine additional study centers in Norway by trained medical staff employed at the Norwegian
University of Science and Technology (NTNU) in Trondheim. Mothers were informed of
their allocation after the last delivery in the PregMet-study, but were requested not to inform
study staff, who were blinded for group allocation during data collection.
Information on sex, age, ethnicity, presence or history of body odor or acne, and a general
medical history was obtained by standardized interviewer-administered questionnaires. Tan-
ner stage was determined either by direct evaluation, or by the parent/guardian in accordance
with the illustrations of the Tanner scale [31].
Height was measured with a Seca stadiometer. Head circumference was measured over the
most prominent part of the occiput, and just above the supraorbital ridge with a measuring
tape. Waist circumference was measured at the minimal waist with a measuring tape. Total
body weight was measured on an InBody 720 (BIOSPACE, Korea) in children included at
St. Olavs University Hospital. The 43 children included at other study sites were weighed on a
digital weighing scale. Body Mass Index (BMI) was calculated from the formula: weight (kg) /
height (m)2. As the age at inclusion of the children varied, all anthropometric measurements
were converted to z-scores according to gender and age from a Norwegian reference popula-
tion, the Bergen growth Study 1 [32, 33]. Blood pressure and heart rate were measured 3 times
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after >10 minutes seated rest,>2 minutes apart. The mean of the two last measurements was
included in the statistical analysis.
Biochemical analyses
Blood samples were drawn from an antecubital vein between 0800 and 1100 h after an over-
night fast. Serum was stored at -80˚C and thawed once before analysis. Androstenedione, tes-
tosterone, cortisol, 17-hydroxyprogesterone and 11-deoxycortisol were analyzed by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) at the Hormone Laboratory, Hau-
keland University Hospital, Bergen, Norway. The LC-MS/MS analyses were accredited by
Norsk Akkreditering 14.12.2018 (NS-EN ISO 15189 (2012)). The inter-assay coefficients of
variation were < 20% for all steroid hormones analyzed. The lower limits of quantification
were 0.02 nmol/l for testosterone, 0.12 nmol/l for androstenedione, 0.24 nmol/l for 17-hydro-
xyprogesterone, 0.1 nmol/l for 11-deoxycortiol and 1.95 nmol/l for cortisol [34].
In the PedMet-study, sex hormone binding globulin (SHBG) was analyzed at the Hormone
Laboratory, Oslo University Hospital, Oslo, Norway by non-competitive immunolumino-
metric assay (ILMA). Free testosterone index was calculated as the percentage of total testos-
terone divided by SHBG.
Hormone z-scores were interpolated from the “Bergen Growth Study 2” references for
male [35] and female [36] hormones rendered by the generalized additive model for location,
scale and shape (GAMLSS) package in R (R Core Team, Vienna, Austria). Briefly, the LMS
method for normalized growth standards [37] enables the calculation of z-scores for new
observations in relation to the smooth (L), mean (M) and coefficient of variation (S) curves.
For the current study, all z-scores therefore represent the sex- and age-adjusted equivalents of
the indicated measurement, in relation to the previously described population samples of
healthy 6- to 16 year-old Norwegian children [24, 38, 39].
Blood samples of control subjects from the Bergen Growth Study 2 were analyzed at the
Hormone Laboratory, Haukeland University Hospital, Bergen. Steroid hormones were ana-
lyzed by LC-MS/MS, as described above, and SHBG by chemiluminescent immunoassay
(CLIA) on Immulite 2000xpi kit (Siemens Healthineers, Germany) [34].
Statistical analyses
Data entry, management and analyses were performed at the Department of Clinical and
Molecular Medicine at the Norwegian University of Science and Technology. The impact of
maternal PCOS on steroid hormones and SHBG was examined by assessing the deviation in z-
scores between the placebo group and the reference population (z-score zero), by one-sample
t-tests. To compare the BMI and the waist circumference z-scores in the placebo group and
controls from the Bergen Growth Study 2, independent samples t-tests were performed. Dif-
ferences between the placebo and metformin groups of steroid hormones and SHBG z-scores,
maternal baseline characteristics, pregnancy outcomes and anthropometric measurements
were analyzed on IBM SPSS Statistics version 22.0 (IBM, SPSS inc USA, Chicago IL) by a two-
sample t-test for continuous variables and a chi-square or Fishers exact test for categorical vari-
ables. To estimate the potential effects of maternal PCOS and metformin on offspring hor-
mones not mediated through changes in BMI, maternal PCOS and metformin effects on
hormone z-scores were adjusted for offspring BMI z-scores, by linear regression analyses. Sub-
group analyses according to gender were performed, as the levels of steroid hormones vary
between sexes also before puberty, and as both maternal PCOS and metformin in pregnancy
might affect steroid hormones differently according to sex [40]. Multiple primary endpoints—
hormone z-scores, Tanner stage and signs of puberty—were adjusted for by the Holm-
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Bonferroni procedure, with a family-wise error rate at 5% [41, 42]. Also Insulin like Growth
Factor-1, DHEAS, Anti Mullerian Hormone, fT4 and TSH were measured in children from
the PregMet study, but as they have not been analyzed in the Bergen Growth Study 2, they
could neither be converted to z-scores, nor age-adjusted and are therefore less accurate, and
were not included in the final analyses.
Results
From April 2014 to July 2016, we included 141 children in the PedMet-study. Blood samples
were drawn, and steroid hormone levels determined in 117 (46%) of the invited children (Fig
1). The participation rate was 48% in the metformin group, and 43% in the placebo group
(p = 0.29).
Maternal baseline characteristics, mode of conception, metformin use at conception, preg-
nancy outcomes, birth anthropometrics and breastfeeding in participants vs non-participants
and in the treatment groups are presented in S1–S3 Tables, and were comparable between
groups.
The mean age of the children at follow-up was 7.4 years ± 1.2 SD (Table 1).
Fig 1. Flow chart of the PregMet and PedMet studies.
https://doi.org/10.1371/journal.pone.0257186.g001
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The maternal PCOS effect
The impact of maternal PCOS on steroid hormones was examined by assessing the deviation
in z-scores between the placebo-exposed children and children from the Bergen Growth Study
2 (z-score zero).
Children of mothers with PCOS (boys and girls) had significantly higher mean z-score of
androstenedione (0.53 (95% confidence interval (CI) 0.27 to 0.79) p = 0.0001), testosterone
(0.53 (95% CI 0.29 to 0.77), p<0.0001), and free testosterone (0.67 (95% CI 0.38 to 0.96),
p<0.0001) than children from the Bergen Growth Study 2 (Table 2A). There was a tendency
towards higher cortisol (0.34 (95% CI 0.08 to 0.61), p = 0.012) and 17-hydroxyprogesterone
(0.42 (95% CI 0.15 to 0.69), p = 0.003), but the difference was not significant after Holm-Bon-
ferroni adjustment.
Hormone levels not converted to z-scores are presented in the S4 Table.
In boys born to women with PCOS, there was a non-significant higher mean cortisol z-
score (0.51 (95% CI 0.17 to 0.84), p = 0.005) after Holm-Bonferroni adjustment, and otherwise
no difference in hormone levels compared to boys from the Bergen Growth Study 2
(Table 2B).
Girls of mothers with PCOS had higher mean z-score of androstenedione (0.73 (95% CI
0.41 to 1.06), p<0.0001) testosterone (0.76 (95% CI 0.51 to 1.00), p<0.0001) and free testoster-
one (0.99 (95% CI 0.67 to 1.32), p<0.0001), than girls from the Bergen Growth Study 2
(Table 2C). There was a non-significant higher 17-hydroxyprogesterone z-score (0.44 (95% CI
0.11 to 0.76), p = 0.01), and lower of SHBG z-score (-0.51 (95% CI -0.83 to-0.19), p = 0.003),
after Holm-Bonferroni adjustments. Adjustment for the BMI z-scores of the children had little
impact on the estimated effect of maternal PCOS on the hormone z-scores in children (S5
Table). Additional adjustment for offspring waist circumference z-scores did not change the
effect estimates (data not shown).
Children born to women with PCOS tended to have higher mean BMI z-scores (mean dif-
ference 0.40 (95% CI 0.13 to 0.68), p = 0.004, and waist circumference z-scores (mean differ-
ence: 0.74, 95% CI 0.56 to 0.92, p = 0.0001) than children in the Bergen Growth Study 2. In
boys, the mean difference in BMI z-score was 0.27, (95% CI -0.11 to 0.65), p = 0.168, while the
mean difference in waist circumference z-score was 0.72 (95% CI 0.47 to 0.98), p = 0.0001. In
girls, the mean difference in BMI z-score was 0.51 (95% CI 0.13 to 0.90), p = 0.009, and the
mean difference in waist circumference z-score was 0.75 (95% CI 0.49 to 1.02), p = 0.0001.
Table 1. Age, Tanner stage and signs of puberty in the children (n = 117) at inclusion at 5–10 years of age.
Children of both sexes Boys Girls
Placebo, Metformin, n = 63 Placebo, Metformin, n = 31 Placebo, Metformin, n = 32
n = 54 n = 24 n = 30
Age, years 7.46 ± 1.18 7.40 ± 1.21 7.54 ± 1.22 7.56 ± 1.23 7.40 ± 1.16 7.23 ± 1.219
Tanner stage, n
I 50 (93) 61 (96) 22 (92) 31 (100) 28 (93) 30 (94)
II 4 (7) 1 (2) 2 (8) 0 (0) 2 (7) 1 (3)
III 0 (0) 1 (2) 0 (0) 0 (0) 0 (0) 1 (3)
Body odor, n 6 (11) 10 (16) 2 (8) 5 (16) 4 (13) 5 (16)
Acne/oily skin, n 2 (4) 3 (5) 0 (0) 1 (3) 2 (7) 2 (6)
Data presented as mean ± Standard Deviation or numbers (%) as appropriate.
None of the comparisons had a p-value under 0.05.
https://doi.org/10.1371/journal.pone.0257186.t001
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The metformin effect
There was a non-significant higher mean 17-hydroxyprogesterone z-score in the metformin
group than in the placebo group (mean difference 0.41 (95% CI 0.08 to 0.74), p = 0.015), and
otherwise no difference when assessing both sexes, after Holm-Bonferroni adjustment
(Table 2A).
Metformin-exposed boys had non-significant higher 11-deoxycortisol z-score than placebo
exposed boys (mean difference 0.65 (95% CI 0.14 to 1.17), p = 0.014, after Holm-Bonferroni
Table 2. Steroid hormone z-scores in children from the placebo and metformin groups.
a) Children of both sexes
The maternal PCOS effecta The metformin effectb
Placebo, n = 54 p Metformin, n = 63 Δ M-P (95% CI) p
Mean (95% CI) Mean (95% CI)
Androstenedione z-score 0.53 (0.27 to 0.79) .0001� 0.66 (0.41 to 0.91) 0.13 (-0.23 to 0.49) .470
Testosterone z-score 0.53 (0.29 to 0.77) < .0001� 0.53 (0.30 to 0.76) 0.00 (-0.33 to 0.33) .995
SHBG z-score -0.28 (-0.55 to 0.00) .051 -0.28 (-0.51 to -0.05) 0.01 (-0.36 to 0.34) .973
Cortisol z-score 0.34 (0.08 to 0.61) .012 0.69 (0.42 to 0.96) 0.35 (-0.03 to 0.72) .070
17-OH-progesterone z-score 0.42 (0.15 to 0.69) .003 0.83 (0.62 to 1.04) 0.41 (0.08 to 0.74) .015
11-deoxycortisol z-score 0.13 (-0.11 to 0.37) .269 0.46 (0.22 to 0.69) 0.32 (-0.01 to 0.66) .056
Free testosterone z-score 0.67 (0.38 to 0.96) < .0001� 0.63 (0.35 to 0.91) -0.04(-0.44 to 0.36) .841
b) Boys
The maternal PCOS effecta The metformin effectb
Placebo, n = 24 p Metformin, n = 31 Δ M-P (95% CI) p
Mean (95% CI) Mean (95% CI)
Androstenedione z-score 0.27 (-0.15 to 0.69) .195 0.74 (0.45 to 1.02) 0.46 (-0.02 to 0.95) .058
Testosterone z-score 0.25 (-0.20 to 0.70) .264 0.54 (0.22 to 0.85) 0.29 (-0.23 to 0.81) .268
SHBG z-score 0.03 (-0.45 to 0.51) .905 -0.43 (-0.75 to -0.11) -0.46 (-0.99 to 0.08) .096
Cortisol z-score 0.51 (0.17 to 0.84) .005 0.82 (0.37 to 1.27) 0.31 (-0.27 to 0.89) .284
17-OH-progesterone z-score 0.40 (-0.07 to 0.87) .089 0.93 (0.61 to 1.24) 0.53 (-0.00 to 1.06) .052
11-deoxycortisol z-score 0.08 (-0.31 to 0.47) .670 0.74 (0.38 to 1.09) 0.65 (0.14 to 1.17) .014
Free testosterone z-score 0.25 (-0.23 to 0.73) .292 0.67 (0.34 to 1.00) 0.42 (-0.13 to 0.97) .133
c) Girls
The maternal PCOS effecta The metformin effectb
Placebo, n = 30 p Metformin, n = 32
Mean (95% CI)
Δ M-P (95% CI) p
Mean (95% CI)
Androstenedione z-score 0.73 (0.41 to 1.06) < .0001� 0.59 (0.16 to 1.01) -0.15 (-0.68 to 0.38) .580
Testosterone z-score 0.76 (0.51 to 1.00) < .0001� 0.53 (0.18 to 0.88) -0.23 (-0.66 to 0.19) .280
SHBG z-score -0.51(-0.83 to-0.19) .003 -0.13 (-0.47 to 0.20) 0.37 (-0.08 to 0.83) .104
Cortisol z-score 0.21 (-0.19 to 0.61) .291 0.56 (0.24 to 0.89) 0.35 (-0.15 to 0.86) .165
17-OH-progesterone z-score 0.44 (0.11 to 0.76) .010 0.74 (0.44 to 1.03) 0.30 (-0.13 to 0.73) .162
11-deoxycortisol z-score 0.18 (-0.14 to 0.49) .291 0.19 (-0.11 to 0.48) 0.01 (-0.41 to 0.44) .952
Free testosterone z-score 0.99 (0.67 to 1.32) < .0001� 0.59 (0.12 to 1.06) -0.40 (-0.96 to 0.16) .157
�p-values statistically significant after Holm-Bonferroni adjustment.
aThe impact of maternal PCOS on steroid hormones was assessed by the deviation in z-scores between the placebo group and the reference population (z-score zero) by
one sample t-tests.
bΔ M-P expresses the metformin effect on hormone mean z-scores, assessed by two sample t-tests.
All z-scores were calculated from the Bergen Growth Study 2 references, according to gender and age.
CI: confidence interval; SHBG: sex hormone binding globulin.
https://doi.org/10.1371/journal.pone.0257186.t002
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adjustment. Other hormones did not differ between metformin and placebo-exposed boys
(Table 2B).
There were no difference in hormone levels between metformin- and placebo-exposed girls
(Table 2C). Adjusting for BMI z-scores in the children had little impact on the estimated effect
of metformin on hormone z-scores in the children (S6 Table). Additional adjustment for off-
spring waist circumference z-scores also had little effect on the estimated effect (data not
shown).
Most children had Tanner stage 1, and no signs of puberty. There was no difference in dis-
tribution of Tanner stages and signs of puberty between the groups (Table 1). As previously
published, there was a tendency towards higher waist circumference z-score and waist-to-
height ratio z-score in metformin vs placebo exposed boys (Table 3) [14].
Discussion
In this study, daughters of women with PCOS had increased levels of androgens compared to
the reference population. Boys exposed to metformin in utero tended to have higher levels of
11-deoxycortisol.
The maternal PCOS effect
The possible altered steroidogenesis in daughters of women with PCOS, as suggested by our
findings of higher androgens, might be due to effects on adrenal glands, ovaries or fat tissue.
Tendencies towards a lower SHBG z-score and a significantly increased free testosterone z-
score was observed among girls [28], and androstenedione z-score, which normally increases
in early puberty, was higher in PCOS children than controls [43]. In puberty, SHBG levels
tend to decrease, while androgens tend to increase, both indicating an increased risk of earlier
puberty among PCOS offspring [27, 28, 44]. An earlier adrenal or gonadal maturation in
daughters of women with PCOS can therefore not be excluded. The BMI and waist
Table 3. Anthropometrics and measures of glucose homeostasis, all children (n = 122) at inclusion, and according to gender.
Children of both sexes Boys Girls
Placebo Metformin p Placebo Metformin p Placebo Metformin p
N = 54 N = 63 N = 24 N = 31 N = 30 N = 32
Anthropometrics
BMI z-score 0.26 (-0.03 to
0.54)
0.53 (0.22 to 0.84) .20 0.10 (-0.31 to
0.45)
0.60 (0.15 to 1.04) .10 0.38 (-0.05 to
0.81)
0.46 (0.01 to 0.93) .78
Weight z-score 0.23 (-0.10 to
0.55)
0.51 (0.22 to 0.81) .19 0.11 (-0.34 to
0.57)
0.63 (0.20 to 1.06) .10 0.32 (-0.16 to
0.79)
0.39 (-0.04 to 0.83) .81













WC z-score 0.51 (0.27 to 0.74) 0.81 (0.56 to 1.07) .09 0.34 (0.08 to 0.60) 0.91 (0.55 to 1.26) .02 0.64 (0.26 to 1.02) 0.72 (0.33 to 1.11) .76
WHtR z-score 0.47 (0.26 to 0.69) 0.82 (0.56 to 1.07) .06 0.28 (0.01 to 0.55) 0.84 (0.48 to 1.20) .02 0.67 (0.33 to 1.00) 0.79 (0.39 to 1.19) .63
Glucose homeostasis
measures
Insulin C-peptide 0.30 ± 0.17 0.32 ± 0.22 .61 0.29 ± 0.18 0.36 ± 0.29 .28 0.31 ± 0.16 0.28 ± 0.13 .42
HbA1c 5.05 ± 0.22 5.05 ± 0.18 .67 5.08 ± 0.23 5.12 ± 0.17 .46 5.03 ± 0.22 5.01 ± 0.18 .81
Fasting glucose 4.75 ± 0.45 4.71 ± 0.49 .65 4.77 ± 0.44 4.80 ± 0.54 .87 4.74 ± 0.49 4.63 ± 0.44 .41
Data presented as mean (95% Confidence Interval) or mean ± Standard Deviation as appropriate.
BMI: body mass index, calculated as height/meter2, WC = waist circumference; WHtR: waist-to-height ratio.
These data represent a subgroup of previously published data [15].
https://doi.org/10.1371/journal.pone.0257186.t003
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circumference of the children born to women with PCOS was higher than in the Bergen
Growth Study 2. In general, an increased BMI in children of this age is related to earlier adre-
nal and gonadal maturation, while adiposity in girls is related to higher levels of testosterone
and lower levels of SHBG, in part due to hyperinsulinemia. Some of the differences in hor-
mones between the groups could therefore relate to the increased central adiposity in this pop-
ulation [23, 28], but adjusting for BMI and waist circumference z-scores had limited impact on
the effect estimates. Measures of glucose homeostasis were not available in the Bergen Growth
Study 2 for comparison.
Stimulation tests with GnRH agonists have shown that ovaries are the source of hyperan-
drogenism in most adult women with PCOS [45]. About 50% of women with PCOS have,
however, increased levels of adrenal androgens, and Maliqueo et al. found that daughters of
women with PCOS more often had exaggerated adrenarche and earlier bone maturation than
controls [9]. Signs of early pubertal maturation, higher prevalence of PCOM, higher levels of
AMH, testosterone, 17-hydroxyprogesterone, DHEAS and lower SHBG have also been
described among daughters of women with PCOS [8–11, 46–48]. Also in sons of women with
PCOS, hormonal characteristics of early pubertal maturation have been described including
higher FSH, androstenedione levels, AMH and bioavailable testosterone, lower SHBG and tes-
ticular volume, but with sperm count comparable to controls [49, 50]. Other studies have
reported no alterations in androgens between PCOS offspring and controls, and the diverging
results are probably due to small study samples and heterogeneity in terms of study design and
population selection [10, 12, 13]. The strongest evidence is, however, in accordance with the
present results of higher androgens and earlier pubertal maturation among daughters of
women with PCOS.
The metformin effect
There were tendencies towards higher levels of 11-deoxycortisol (boys only) and 17-hydroxy-
progesterone (total sample) in the metformin group. 11-deoxycortisol is a glucocorticoid and
mainly a precursor of the more potent cortisol, but might also be converted to androstenedi-
one [51]. 17-hydroxyprogesterone is a progestogen, and a precursor of 11-deoxycortisol and
androstenedione [52]. We have previously published, and observed also in the present sub-
population, tendencies of increased BMI and waist circumference in the metformin group
[14]. Increased levels of cortisol, of which 11-deoxycortisol is a precursor, have repeatedly
been associated to overweight, irrespective of age, but the mechanism behind remains unex-
plained [53]. Some impact on steroid hormones and SHBG could be expected from the trend
towards higher measures of adiposity in the metformin group. Adjusting for BMI and waist
circumference z-scores had, however, little impact on the effect estimates of metformin. How
metformin in utero potentially might impact these steroid precursors independently of BMI is
not known, and the clinical significance of this finding is uncertain.
Two systematic reviews and meta-analyses of RCTs on metformin vs placebo/insulin in
PCOS pregnancies or in gestational diabetes mellitus supports a higher weight among metfor-
min exposed children, which in turn might impact the timing of puberty [20, 21, 23]. The evi-
dence on how metformin in utero might influence hormonal levels and maturation in
childhood is essentially lacking. While mice exposed to metformin in utero had reduced testic-
ular size, and human fetal gonads exposed to metformin in vitro had reduced testosterone
secretion [54], no association was found between metformin and testicular size of 52 children
at ~5 years of age, after their mothers were randomized to metformin or insulin for the treat-
ment of gestational diabetes mellitus [26]. In the present study, the metformin and placebo
groups did not differ in DHEAS, androstenedione levels or in signs of clinical androgen action.
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However, whether metformin, or the increased central adiposity related to it, impact pubertal
development is uncertain based on our findings, as the mean age was only 7.5 years, and as few
of the children had reached puberty.
Based on the present results, an effect of metformin on offspring steroid hormones cannot
be excluded. The results from studies where metformin was used in PCOS pregnancies imply a
particularly cautious follow up of these children in order to prevent overweight and the associ-
ated risk of early puberty [14, 15, 23, 24].
An obvious strength of this study is the study design—a follow-up of a randomized pla-
cebo-controlled, double blind study: the PregMet-study. The metformin and placebo groups
were comparable at baseline. The PregMet-study population represented a broad spectrum of
women with known PCOS diagnosis and good compliance to study medication. It is uncertain
whether the results of this study are applicable to women without PCOS, without known
PCOS, or to women who differ from the PregMet-population in ethnicity, BMI or other char-
acteristics. Both the PregMet and the PedMet-studies adhered to strict methodology, and
examinations were performed by trained study personnel. Steroid hormone analyses were per-
formed by LC-MS/MS, which, compared to immunoassays, offers superior analytical specific-
ity, sensitivity and accuracy, even at low concentrations. The reference population consists of a
large random sample of Norwegian children.
This study has some limitations. The follow-up rate is low: 46%. However, maternal base-
line characteristics were comparable between participants and non-participants. The low fol-
low-up rate, combined with small numbers, multiple tests and subgroup analyses increases the
risk of random errors and false positive findings. Holm-Bonferroni adjustments were per-
formed to account for this.
Conclusion
Elevated androgen levels were present in preadolescent daughters of women with PCOS, indi-
cating higher risk of early pubertal maturation. Metformin exposed boys tended to have higher
levels of 11-deoxycortisol compared to placebo exposed boys, and a modifying effect on ste-
roidogenesis of metformin exposure in utero cannot be excluded. Our findings need to be con-
firmed by studies on offspring who have entered puberty.
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